JP2016522830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522830A5 JP2016522830A5 JP2016514532A JP2016514532A JP2016522830A5 JP 2016522830 A5 JP2016522830 A5 JP 2016522830A5 JP 2016514532 A JP2016514532 A JP 2016514532A JP 2016514532 A JP2016514532 A JP 2016514532A JP 2016522830 A5 JP2016522830 A5 JP 2016522830A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pbmc
- use according
- derived
- degeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cells Anatomy 0.000 claims 11
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 230000002757 inflammatory Effects 0.000 claims 7
- 210000001616 Monocytes Anatomy 0.000 claims 6
- 208000009745 Eye Disease Diseases 0.000 claims 5
- 208000002780 Macular Degeneration Diseases 0.000 claims 3
- 210000001328 Optic Nerve Anatomy 0.000 claims 3
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 3
- 230000004380 optic nerve Effects 0.000 claims 3
- 230000002207 retinal Effects 0.000 claims 3
- 235000020945 retinal Nutrition 0.000 claims 3
- 239000011604 retinal Substances 0.000 claims 3
- 201000007737 retinal degeneration Diseases 0.000 claims 3
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 2
- 102100003268 CD14 Human genes 0.000 claims 2
- 101700027514 CD14 Proteins 0.000 claims 2
- 102100005826 CD19 Human genes 0.000 claims 2
- 101700087100 CD19 Proteins 0.000 claims 2
- 102100015541 FCGR3A Human genes 0.000 claims 2
- 101710044656 FCGR3A Proteins 0.000 claims 2
- 101710044657 FCGR3B Proteins 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010023332 Keratitis Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 2
- 210000001525 Retina Anatomy 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 2
- 230000003412 degenerative Effects 0.000 claims 2
- 230000001537 neural Effects 0.000 claims 2
- 210000002569 neurons Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 claims 1
- 206010023365 Keratopathy Diseases 0.000 claims 1
- 102100007544 NCAM1 Human genes 0.000 claims 1
- 101700077124 NCAM1 Proteins 0.000 claims 1
- 206010030032 Ocular disorder Diseases 0.000 claims 1
- 241001420836 Ophthalmitis Species 0.000 claims 1
- 208000010403 Panophthalmitis Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 201000002287 keratoconus Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Claims (10)
- 網膜または視神経において、神経細胞変性の抑制、グルタミン酸塩の毒性からの神経細胞の保護または神経再生の促進により、網膜または視神経を損傷する眼疾患、眼障害または眼病態を治療するための医薬組成物を調製するための、末梢血単核細胞（PBMC）由来単球亜集団の使用であって、
該単球亜集団が、CD3+細胞、CD19+細胞、CD56+細胞およびCD16 + 細胞を相対的少量しか含んでいないか、またはこれらの細胞を実質的に含んでいないことを特徴とするPBMC由来単球亜集団の使用。 - 前記PBMC由来単球亜集団は、CD14+細胞が実質的に濃縮されている、請求項１に記載の使用。
- 前記疾患、障害または病態が、加齢黄斑変性および網膜色素変性から選択される網膜変性障害；前部虚血性視神経症；緑内障；ならびにぶどう膜炎から選択される、請求項１または２に記載の使用。
- 炎症性眼疾患、炎症性眼障害または炎症性眼病態を治療するための医薬組成物を調製するための末梢血単核細胞（PBMC）由来単球亜集団の使用であって、
該単球亜集団が、CD3+細胞、CD19+細胞、CD56+細胞およびCD16 + 細胞を相対的少量しか含んでいないか、またはこれらの細胞を実質的に含んでいないことを特徴とするPBMC由来単球亜集団の使用。 - 前記PBMC由来単球亜集団は、CD14+細胞が実質的に濃縮されている、請求項４に記載の使用。
- 炎症性眼疾患、炎症性眼障害または炎症性眼病態による損傷を有する網膜または視神経において、神経細胞変性の抑制、グルタミン酸塩の毒性からの神経細胞の保護または神経再生の促進を行うための、請求項４または５に記載の使用。
- 前記疾患、障害または病態が、加齢黄斑変性および網膜色素変性から選択される網膜変性障害；前部虚血性視神経症；緑内障；ならびにぶどう膜炎から選択される、請求項６に記載の使用。
- 強膜炎、角膜炎、角膜潰瘍、雪眼炎、タイゲソン点状表層角膜症、角膜血管新生、フックスジストロフィー、円錐角膜、乾性角結膜炎および虹彩炎から選択される炎症性眼疾患を治療するための、請求項４または５に記載の使用。
- 前記PBMC由来単球亜集団は、注射用製剤である、請求項７または８に記載の使用。
- 前記PBMC由来単球亜集団は、眼内注射用製剤である、請求項９に記載の使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826159P | 2013-05-22 | 2013-05-22 | |
| US61/826,159 | 2013-05-22 | ||
| US201361915069P | 2013-12-12 | 2013-12-12 | |
| US61/915,069 | 2013-12-12 | ||
| PCT/IL2014/050463 WO2014188436A1 (en) | 2013-05-22 | 2014-05-22 | Human monocyte sub-population for treatment of eye diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522830A JP2016522830A (ja) | 2016-08-04 |
| JP2016522830A5 true JP2016522830A5 (ja) | 2017-06-29 |
| JP6474082B2 JP6474082B2 (ja) | 2019-02-27 |
Family
ID=51933057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514532A Active JP6474082B2 (ja) | 2013-05-22 | 2014-05-22 | 眼疾患および眼障害の治療のためのヒト単球亜集団 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10188679B2 (ja) |
| EP (1) | EP2999479B1 (ja) |
| JP (1) | JP6474082B2 (ja) |
| KR (1) | KR102257163B1 (ja) |
| CN (1) | CN105377273A (ja) |
| AU (1) | AU2014269935B2 (ja) |
| BR (1) | BR112015029299A2 (ja) |
| CA (1) | CA2913274C (ja) |
| IL (1) | IL242694B (ja) |
| MX (1) | MX2015016062A (ja) |
| WO (1) | WO2014188436A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014014560A8 (pt) * | 2011-12-14 | 2017-07-04 | Yeda Res & Dev | subpopulação de monócitos humanos para tratamento de lesões do sistema nervoso central |
| CA2997763A1 (en) | 2015-09-08 | 2017-03-16 | Cellular Dynamics International, Inc. | Macs-based purification of stem cell-derived retinal pigment epithelium |
| DE102017125335B4 (de) * | 2017-10-27 | 2019-10-17 | Epiontis Gmbh | Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten |
| KR102228401B1 (ko) * | 2018-07-05 | 2021-03-16 | 고려대학교 산학협력단 | 유리체 절제술 및 안구 내 mnu 주입과 제거를 이용한 망막 변성 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800812A (en) | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
| US6267955B1 (en) | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
| MXPA04004813A (es) | 2001-11-21 | 2004-08-11 | Yeda Res & Dev | Procedimientos para la produccion de leucocitos fagociticos mononucleares humanos. |
| AU2006229687B2 (en) * | 2005-02-24 | 2011-08-11 | The Scripps Research Institute | Isolated myeloid-like bone marrow cell populations and methods of treatment therewith |
| EA201190109A1 (ru) | 2009-02-20 | 2012-07-30 | Зе Скрипс Ресеч Инститьют | Изолированные популяции моноцитов и связанные с ними терапевтические применения |
| BR112014014560A8 (pt) | 2011-12-14 | 2017-07-04 | Yeda Res & Dev | subpopulação de monócitos humanos para tratamento de lesões do sistema nervoso central |
-
2014
- 2014-05-22 KR KR1020157036168A patent/KR102257163B1/ko active IP Right Grant
- 2014-05-22 BR BR112015029299A patent/BR112015029299A2/pt not_active Application Discontinuation
- 2014-05-22 CA CA2913274A patent/CA2913274C/en active Active
- 2014-05-22 AU AU2014269935A patent/AU2014269935B2/en active Active
- 2014-05-22 CN CN201480039692.9A patent/CN105377273A/zh active Pending
- 2014-05-22 MX MX2015016062A patent/MX2015016062A/es unknown
- 2014-05-22 EP EP14801769.2A patent/EP2999479B1/en active Active
- 2014-05-22 JP JP2016514532A patent/JP6474082B2/ja active Active
- 2014-05-22 US US14/898,732 patent/US10188679B2/en active Active
- 2014-05-22 WO PCT/IL2014/050463 patent/WO2014188436A1/en active Application Filing
-
2015
- 2015-11-19 IL IL242694A patent/IL242694B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3045733C (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
| WO2017158366A3 (en) | Ophthalmic delivery device and ophthalmic drug compositions | |
| JP2016522830A5 (ja) | ||
| JP2012505162A5 (ja) | ||
| JOP20170147B1 (ar) | تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة | |
| PH12015502587A1 (en) | Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same | |
| JP2018516869A5 (ja) | ||
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| Hu et al. | Knockout of Ccr2 alleviates photoreceptor cell death in rodent retina exposed to chronic blue light | |
| NZ592057A (en) | Sulfur-linked compounds for treating opthalmic diseases and disorders | |
| RU2017116974A (ru) | Офтальмологическая композиция, содержащая циклоспорин и трегалозу | |
| JP2013528563A5 (ja) | ||
| WO2013184650A3 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
| JP2015514760A5 (ja) | ||
| AR079683A1 (es) | Formulacion topica oftalmica de peptidos | |
| BR112015029299A2 (pt) | subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares | |
| El-Nimri et al. | Effect of chronic topical latanoprost on the sclera and lamina cribrosa of form-deprived myopic Guinea pigs | |
| NZ600040A (en) | Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method. | |
| MA50991B1 (fr) | Composition topique ophtalmique comprenent de l'acide dobesilique pour le traitement des maladies du segment postérieur de l' il | |
| Baig et al. | Recommendations for the management of Acanthamoeba keratitis | |
| Amalnath et al. | Ocular signs in Wilson disease | |
| Nam et al. | Effects and prognostic factors of automated thermodynamic system treatment for meibomian gland dysfunction | |
| Roshan et al. | Effectiveness of Wobble Board Balance Training in Patients with Benign Paroxysmal Positional Vertigo (BPPV) after Canalith Repositioning Maneuver. | |
| JP2015502368A5 (ja) | ||
| RU2559580C1 (ru) | Препарат для лечения синдрома "сухого глаза" |